Clinical Trial Update: Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001) [Phase 2]

View source ↗

Summary

This clinical trial update reports the Phase 2 study of luspatercept for anemia in patients with myelodysplastic syndrome (MDS); the trial has completed and res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Myelodysplastic Syndrome

Drugs mentioned

• Luspatercept (Reblozyl) (luspatercept)

Snippet

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: Anemia | Phase 2 | Status: COMPLETED | Results posted: 2024-07-29